DVA logo

DAVITA INC

DVANYSE
πŸ† #818 by market capEarnings Oct 23 Β· PostUS Equity
$175.26β–Ό $2.77 (βˆ’1.58%)
Live
πŸ””
Track DVA
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 1.6%
7dβ–Ό 4.6%
14dβ–Ό 8.2%
30dβ–Ό 3.0%
ytdβ–² 54.2%
1yβ–² 34.2%
🏦Market Cap
$11.25B
Mid Cap
πŸ“ˆRevenue Growth (YoY)
+6.5%
Slowing
πŸ“ŠGross Margin
31.0%
Moderate
πŸ’΅FCF Margin
11.5%
Healthy
βš–οΈP/S Ratio
0.8x
Cheap
Otter Score
68
Fair

Trading Snapshot

Day Range
$173.77 – $176.51
52-Week Range
$101.00 – $247.49
Volume
$2.49B
Avg Volume
$2.15B
Shares Outstanding
64.2M
Next Earnings
Oct 31, 2026

Fundamentals Snapshot

Annual Revenue
$13.64B
Last Q Revenue
$3.55B
P/E Ratio
15.1
P/S Ratio
0.8x
EPS (TTM)
$13.08
Dividend Yield
0.00%
Dilution (1yr)
+5.1%

Why Investors Own DVA

  • βœ“High-growth profile β€” revenue up +57.1% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 72% gross margin and 30% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

DVA logo

DAVITA INC

DVA
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$13.6Bβ–² +6.5% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
27.0%β–Ό βˆ’17.9% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$2.0Bβ–Ό βˆ’3.8% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$1.3Bβ–Ό βˆ’10.6% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
88.1Mβ–² +5.1% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$14.3Bβ–Ό βˆ’$3.0B YoY
StockOtter Β· stockotter.space

About DAVITA INC

DaVita Inc. specializes in delivering essential kidney dialysis treatments and comprehensive renal care to individuals grappling with chronic kidney failure. The company primarily operates an extensive network of outpatient dialysis centers, supplementing this with services provided in hospital inpatient settings and within patients' homes. Beyond direct patient treatment, DaVita manages its own diagnostic laboratories, performing routine tests vital for dialysis patients, alongside other physician-ordered laboratory analyses specifically for those with end-stage renal disease (ESRD). The firm also offers administrative and management support to various other outpatient dialysis facilities. Its broad spectrum of offerings extends to chronic disease management programs, supporting a substantial patient cohort; by year-end 2021, this included 16,000 patients enrolled in risk-based integrated care models and an additional 7,000 in other integrated care arrangements. Further specialized services encompass vascular access interventions, clinical research initiatives, direct physician support, and a complete suite of holistic kidney care solutions. As of December 31, 2021, DaVita's footprint across the United States comprised 2,815 outpatient dialysis centers, collectively serving approximately 203,100 patients. Globally, the company operated 339 outpatient dialysis centers spread across ten countries outside the U.S., attending to roughly 39,900 patients. Moreover, it furnished acute inpatient dialysis services and related laboratory work in around 850 U.S. hospitals. Founded in 1994, DaVita Inc. maintains its headquarters in Denver, Colorado. The company rebranded to its current name in September 2016, having previously been known as DaVita HealthCare Partners Inc.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Fair
68/100

Analyst Ratings

β“˜
Consensus
Buy
13 analysts
Strong Buy1
Buy6
Hold5
Sell1
Strong Sell0
Ratings as of Sep 2026

Latest News & Updates

πŸš€
The Motley FoolΒ·13h ago

This Warren Buffett Stock Is Up 58%. History Says This Is What Happens Next.

DaVita reported double-digit EPS growth in the second quarter. Berkshire Hathaway owns roughly 45% of DaVita stock.

Zacks Investment ResearchΒ·4d ago

DaVita HealthCare (DVA) Registers a Bigger Fall Than the Market: Important Facts to Note

The latest trading day saw DaVita HealthCare (DVA) settling at $174.67, representing a -4.62% change from its previous close.

MarketBeatΒ·8d ago

3 Surging Stocks That Don't Need the AI Boom to Keep Winning

With AI companiesβ€”and related chip stocksβ€”driving much of the market's performance this year, it's understandable that some investors are hesitant to put all their trust in a burgeoning industry, no matter how much momen

Zacks Investment ResearchΒ·12d ago

DaVita HealthCare (DVA) Advances While Market Declines: Some Information for Investors

DaVita HealthCare (DVA) closed the most recent trading day at $193.86, moving +1.55% from the previous trading session.

BenzingaΒ·13d ago

Warren Buffett, Donald Trump Bet on Same 17 Stocks β€” Some Might Surprise You

President Donald Trump has disclosed over 20,000 stock trades made over the past 12 months. The trades, which the White House says Trump has no knowledge of, span a wide range of sectors and dollar amounts.

GuruFocusΒ·14d ago

A Look at DaVita Inc (DVA) After 4.3% Gain -- GF Value $195.67 vs Price $189.32

On September 14, 2026, DaVita Inc (DVA) shares rose 4.3% to $189.32, reflecting strong momentum as the stock trades within a 52-week range of $101.00 to $247.49